Previous 10 | Next 10 |
– Company ended the quarter with $ 53.8 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc....
Aeterna Zentaris ( NASDAQ: AEZS ) on Monday said it would regain the U.S. and Canadian rights for Macrilen, an oral test to detect adult growth hormone deficiency, from Danish pharmaceutical company Novo Nordisk ( NVO ). The company said it would get the rights back af...
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the o ngoing pivotal Phase 3 study “DETECT-trial" of mac...
Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.87. Revenue of -$0.2M (vs. $1.6M Y/Y). The company had $58.2M cash and cash equivalents at June 30, 2022 (December 31, 2021 – $65.3M). For further details see: Aeterna Zentaris GAAP EP...
– Company ended the quarter with $58.2 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq:...
The shares of the commercial-stage biotech Aeterna Zentaris ( NASDAQ: AEZS ) dropped ~10% in the morning hours Tuesday after the company disclosed that its previously announced 1-25 reverse stock split would take effect this week. Accordingly, the common shares of Aete...
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced t...
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a d...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...